References
- Thomas R, Sanders S, Doust J, Beller E, Glasziou P. Prevalence of Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis. Pediatrics. 2015;135(4):e994–1001.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC. 5th ed. 2013.
- National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management [NICE guideline NG87]. 2018. https://www.nice.org.uk/guidance/ng87 Accessed 10 June 2022.
- Wolraich ML, Hagan JF, Allan C, Chan E, Davison D, Earls M, et al. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019;144(4):e20192528.
- CADDRA – Canadian ADHD Resource Alliance: Canadian ADHD Practice Guidelines, 4.1 Edition, Toronto ON; CADDRA, 2020.
- Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie Psychosomatik und Psychotherapie (DGKJP), Deutsche Gesellschaft für Psychiatrie und Psychotherapie Psychosomatik und Nervenheilkunde (DGPPN), & Deutsche Gesellschaft für Sozialpädiatrie und Jugendmedizin (DGPSJ). (Hrsg). (2018). Langfassung der interdisziplinären evidenz- und konsensbasierten (S3) Leitlinie „Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Kindes-, Jugend- und Erwachsenenalter“. AWMF-Registernummer 028-045. https://www.awmf.org/uploads/tx_szleitlinien/028-045l_S3_ADHS_2018-06.pdf Accessed 13 June 2022.
- Childress AC, Komolova M, Sallee FR. An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations. Expert Opin Drug Metab Toxicol. 2019;15(11):937–74.
- MEDICE Arzneimittel Pütter GmbH & Co KG. Attentin 5/10/20 mg SmPC. 06/2020.
- Uebel-von Sandersleben H, Dangel O, Fischer R, Ruhmann M, Huss M. Effectiveness and safety of dexamphetamine sulfate (Attentin®) in the routine treatment of children and adolescents with ADHD: results from a 12-month non-interventional study. Scand J Child Adolesc Psychiatr Psychol. 2021;9:73–86.
- European Medicines Agency. EMA/CHMP/EWP/280/96 Rev1. Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms. 2014. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmacokinetic-clinical-evaluation-modified-release-dosage-forms_en.pdf Accessed 13 June 2022
- European Medicines Agency. CPMP/EWP/QWP/1401/98 Rev.1/Corr** Guideline on the Investigation of Bioequivalence. London. 20 January 2010.https://www.ema.europa.eu/en/documents/scientific-guideline/ guideline-investigation-bioequivalence-rev1_en.pdf Accessed 13 June 2022.
- European Generic Medicines Association. Revised EMA Bioequivalence Guideline. Questions & Answers. London. June 2010. https://www.medicinesforeurope.com/wp-content/uploads/2016/03/EGA_BEQ_QA_WEB_QA_1_32.pdf Accessed 13 June 2022.
- Schuirmann DJ. Two at a Time? Or All at Once? International Biometric Society, Eastern North American Region, Spring Meeting. Pittsburgh, PA. March 28–31, 2004.
- D’Angelo P. Testing for Bioequivalence in Higher–Order Crossover Designs: Two-at-a-Time Principle Versus Pooled ANOVA. 2nd Conference of the Global Bioequivalence Harmonisation Initiative. Rockville, MD. 15–16 September, 2016.
- Berger RL, Hsu JC. Bioequivalence Trials, Intersection-Union Tests and Equivalence Confidence Sets. Stat Sci. 1996;11(4):283–302.
- Watanalumlerd P, Christensen JM, Ayres JW. Pharmacokinetic modeling and simulation of gastrointestinal transit effects on plasma concentrations of drugs from mixed immediate-release and enteric-coated pellet formulations. Pharm Dev Technol. 2007;12(2):193–202.
- Markowitz JS, Patrick KS. The Clinical Pharmacokinetics of Amphetamines Utilized in the Treatment of Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2017;27(8):678–89.
- Koziolek M, Alcaro S, Augustijns P, Basit AW, Grimm M, Hens B, et al. The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group. Eur J Pharm Sci. 2019;134:31–59.
- Tulloch SJ, Zhang Y, McLean A, Wolf KN. SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration. Pharmacotherapy. 2002;22(11):1405–15.
- Stark JG, Engelking D, McMahen R, Sikes C. A randomized crossover study to assess the pharmacokinetics of a novel amphetamine extended-release orally disintegrating tablet in healthy adults. Postgrad Med. 2016;128(7):648–55.
- Krishnan S, Zhang Y. Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. J Clin Pharmacol. 2008;48(3):293–302.
- Wang Y, Yu M, Yan B, Martin P, Robertson B. Effects of Food on the Bioavailability of Amphetamine in Healthy Adults After Administration of SHP465 Mixed Amphetamine Salts Extended-Release Capsules. Drugs R D. 2019;19(2):167–75.